Trials / Unknown
UnknownNCT02131688
Phase I Study of Mitoxantrone Hydrochloride Liposome Injection
Phase I Dose Escalation Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Malignant Lymphoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose,the safety and effectiveness of Mitoxantrone Hydrochloride Liposome Injection.
Detailed description
The trial of the dose escalation method is from 18mg/m2 until the maximum tolerated dose and every 3 patient is a dose group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mitoxantrone Hydrochloride Liposome |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2015-08-01
- Completion
- 2015-10-01
- First posted
- 2014-05-06
- Last updated
- 2014-05-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02131688. Inclusion in this directory is not an endorsement.